» Articles » PMID: 12200717

Treatment of HBV-carrying Lymphoma Patients with Rituximab and CHOP: a Diagnostic and Therapeutic Challenge

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2002 Aug 30
PMID 12200717
Citations 13
Authors
Affiliations
Soon will be listed here.
Citing Articles

Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.

Cui R, Lyu C, Li Q, Jiang Y, Mou N, Yang Z Hematol Oncol. 2020; 39(1):75-86.

PMID: 32949412 PMC: 7983916. DOI: 10.1002/hon.2807.


Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Kato M, Atsumi T Rheumatol Int. 2015; 36(5):635-41.

PMID: 26573663 DOI: 10.1007/s00296-015-3395-x.


Hepatitis B virus reactivation with a rituximab-containing regimen.

Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H World J Hepatol. 2015; 7(21):2344-51.

PMID: 26413224 PMC: 4577642. DOI: 10.4254/wjh.v7.i21.2344.


Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study.

Hsiao L, Chiou T, Gau J, Yang C, Yu Y, Liu C Medicine (Baltimore). 2015; 94(32):e1321.

PMID: 26266374 PMC: 4616669. DOI: 10.1097/MD.0000000000001321.


Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.

Ando T, Kojima K, Isoda H, Eguchi Y, Honda T, Ishigami M Int J Hematol. 2015; 102(3):379-82.

PMID: 25842192 DOI: 10.1007/s12185-015-1788-y.